BiotechTube

Dexamethasone + Iberdomide Hydrochloride

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoldering Plasma Cell Myeloma

Conditions

Smoldering Plasma Cell Myeloma

Trial Timeline

Nov 2, 2021 → Sep 1, 2029

NCT ID
NCT04776395

About Dexamethasone + Iberdomide Hydrochloride

Dexamethasone + Iberdomide Hydrochloride is a phase 2 stage product being developed by Bristol Myers Squibb for Smoldering Plasma Cell Myeloma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04776395. Target conditions include Smoldering Plasma Cell Myeloma.

What happened to similar drugs?

0 of 1 similar drugs in Smoldering Plasma Cell Myeloma were approved

Approved (0) Terminated (0) Active (1)
🔄Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04776395Phase 2Recruiting

Competing Products

13 competing products in Smoldering Plasma Cell Myeloma

See all competitors
ProductCompanyStageHype Score
Elotuzumab (BMS-901608; HuLuc63)AbbViePhase 2
35
BHQ880NovartisPhase 2
35
carfilzomib + Lenalidomide + Dexamethasone + MelphalanAmgenPhase 2
39
DenosumabAmgenPhase 2
35
Carfilzomib + Lenalidomide + Daratumumab + DexamethasoneAmgenPhase 2
39
ElranatamabPfizerPhase 2
42
Nivolumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
35
Elotuzumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
35
LinvoseltamabRegeneron PharmaceuticalsPhase 2
39
Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3
47
SelinexorKaryopharm TherapeuticsPhase 2
32
IPH2101Innate PharmaPhase 2
25
PD-L1 peptideIO BiotechPhase 2
17